QWM
ALNY icon

Quaker Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Quaker Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$541 – 904
2025
Q1 		$541 Buy
+2
New +$514 ﹤0.01% 626

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
FAF
Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

Quaker Wealth Management's ALNY Position: Q2 2026 in Review

Quaker Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 50% in Q2 2026, selling an estimated $302 and leaving 1 share worth $302. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Quaker Wealth Management first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $912 in Q3 2025. 211 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Quaker Wealth Management held 1 share of Alnylam Pharmaceuticals worth $302 as of Q2 2026.
  • Quaker Wealth Management sold 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Quaker Wealth Management's portfolio in Q2 2026, its #839 holding.
  • Quaker Wealth Management first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Quaker Wealth Management's Alnylam Pharmaceuticals position peaked at $912 in Q3 2025.
  • 211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Quaker Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.